PXS-5153A is primarily investigated for its potential therapeutic applications in treating fibrotic diseases. It functions as a selective inhibitor of lysyl oxidase-like 2 (LOXL2), an enzyme that plays a critical role in the cross-linking of collagen and elastin, processes that contribute to fibrosis. By inhibiting LOXL2, PXS-5153A aims to reduce the excessive deposition of extracellular matrix components, which is a hallmark of fibrotic conditions. This makes it a promising candidate for treating diseases such as liver fibrosis, pulmonary fibrosis, and kidney fibrosis. Preclinical studies have shown that PXS-5153A can effectively attenuate fibrosis progression in animal models, highlighting its potential as a novel anti-fibrotic agent. Further research and clinical trials are ongoing to evaluate its efficacy and safety in humans.